Your provider may recommend continued therapy, as some patients resume loss after 4-8 weeks of plateau without intervention
In controlled pre-clinical and laboratory settings, Retatrutide has been studied across a wide range of metabolic, endocrinological, and physiological research applications: Triple Incretin Receptor Research Retatrutides defining research application is the simultaneous activation of GLP-1R, GIPR, and GCGR enabling researchers to study the combined tri-agonist incretin effect, examine the distinct contribution of each receptor to overall metabolic outcomes, and explore the additive and synergistic interactions between all three receptor systems in ways no prior compound has allowed
J Clin Invest 91(1):301307
Effects on weight reduction may contribute to improvements in metabolic function
Balancing manufacturing scalability, cost, and patient convenience will be key to future device strategy success
This is consistent with the approach recommended for anyone following the standard tirzepatide dosing schedule for weight loss
